Business News • PR NewsWire • CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis

CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis

CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis

SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, an oral JAK2/FLT3 inhibitor, demonstrating the safety and tolerability profile of...

View More : http://www.prnewswire.com/news-releases/cti-announces-new-data-presented-at-eha-2013-congress-demonstrating-the-safety-a...

Releted News by prnewswire

O.C. Tanner Launches Yearbook™, An Innovative New Suite of Tools To Commemorate Careers; Celebrate Employee Success

Sony Pictures Television Garners Five Daytime Emmy Awards Including Outstanding Talk Show/ Informational for The Dr. Oz Show and Outstanding Drama Series for Days of our Lives

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and 4th Line Salvage Setting With and Without Prior Rituximab Treatment